Previous Close | 0.4250 |
Open | 0.4200 |
Bid | 0.4001 x 34100 |
Ask | 0.4750 x 1800 |
Day's Range | 0.4000 - 0.4400 |
52 Week Range | 0.2870 - 1.9550 |
Volume | |
Avg. Volume | 453,887 |
Market Cap | 75.257M |
Beta (5Y Monthly) | 1.41 |
PE Ratio (TTM) | 8.99 |
EPS (TTM) | 0.0450 |
Earnings Date | Mar 01, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.92 |
As published in The Knee, new study supports Conformis’ longtime assertion that knee joint replacements that are fully personalized to each patient’s unique anatomy may be best to limit post-surgical pain and optimize patient satisfactionBILLERICA, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced results of a published study that investigated the characteristic sha
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright (HCW) Global Investment Conference. The hybrid conference will take place May 23-26, 2022. The conference will be held at the Fontainebleau Miami Beach Hotel and will include virtual
ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?